It was found that overexpression of GPX2 promotes proliferation and invasion, prevents the apoptosis of LNCaP and 22RV1 cells, and triggers the activation of the Wnt/β-catenin and epithelial–mesenchymal transition (EMT) pathways, which are related to the occurrence and development of prostate cancer [123]. Here, GPX2 is linked to prostate carcinoma.